TW202115033A - 酵素抑制劑 - Google Patents

Info

Publication number

TW202115033A

TW202115033A TW109104437A TW109104437A TW202115033A TW 202115033 A TW202115033 A TW 202115033A TW 109104437 A TW109104437 A TW 109104437A TW 109104437 A TW109104437 A TW 109104437A TW 202115033 A TW202115033 A TW 202115033A

Authority

TW

Taiwan

Prior art keywords

pharmaceutically acceptable

compound

racemic

diastereomers

enantiomers

Prior art date

2019-08-21

Links

• Espacenet
• Global Dossier
• Discuss

• 239000002532 enzyme inhibitor Substances 0.000 title description 2
• 150000001875 compounds Chemical class 0.000 claims abstract description 331
• 239000000203 mixture Substances 0.000 claims abstract description 194
• 238000000034 method Methods 0.000 claims abstract description 66
• 150000003839 salts Chemical class 0.000 claims description 260
• 239000012453 solvate Substances 0.000 claims description 245
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 175
• 125000000217 alkyl group Chemical group 0.000 claims description 127
• 125000000623 heterocyclic group Chemical group 0.000 claims description 127
• 108010071241 Factor XIIa Proteins 0.000 claims description 92
• 125000005843 halogen group Chemical group 0.000 claims description 67
• 125000003545 alkoxy group Chemical group 0.000 claims description 66
• 229910052799 carbon Inorganic materials 0.000 claims description 56
• 206010019860 Hereditary angioedema Diseases 0.000 claims description 50
• -1 -OH Chemical group 0.000 claims description 44
• 208000028185 Angioedema Diseases 0.000 claims description 42
• 125000004432 carbon atom Chemical group C* 0.000 claims description 38
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 36
• 239000008194 pharmaceutical composition Substances 0.000 claims description 35
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 34
• 208000007536 Thrombosis Diseases 0.000 claims description 34
• 229910052757 nitrogen Inorganic materials 0.000 claims description 34
• 125000003386 piperidinyl group Chemical group 0.000 claims description 34
• 102100035792 Kininogen-1 Human genes 0.000 claims description 33
• 125000001424 substituent group Chemical group 0.000 claims description 31
• 101800004538 Bradykinin Proteins 0.000 claims description 30
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 30
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 30
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
• 229930195734 saturated hydrocarbon Natural products 0.000 claims description 27
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 26
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 26
• 201000010099 disease Diseases 0.000 claims description 26
• 230000001404 mediated effect Effects 0.000 claims description 26
• 239000003814 drug Substances 0.000 claims description 25
• 239000008280 blood Substances 0.000 claims description 24
• 210000004369 blood Anatomy 0.000 claims description 24
• 230000000694 effects Effects 0.000 claims description 23
• 125000006574 non-aromatic ring group Chemical group 0.000 claims description 22
• 238000011282 treatment Methods 0.000 claims description 20
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 17
• 125000002947 alkylene group Chemical group 0.000 claims description 16
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 13
• 206010020751 Hypersensitivity Diseases 0.000 claims description 12
• 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 11
• 201000006417 multiple sclerosis Diseases 0.000 claims description 11
• 206010014522 Embolism venous Diseases 0.000 claims description 10
• 208000006011 Stroke Diseases 0.000 claims description 10
• 150000002430 hydrocarbons Chemical class 0.000 claims description 10
• 208000004043 venous thromboembolism Diseases 0.000 claims description 10
• 239000004215 Carbon black (E152) Substances 0.000 claims description 9
• 229930195733 hydrocarbon Natural products 0.000 claims description 9
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 8
• 210000004204 blood vessel Anatomy 0.000 claims description 8
• 229910052801 chlorine Inorganic materials 0.000 claims description 8
• 230000015271 coagulation Effects 0.000 claims description 8
• 238000005345 coagulation Methods 0.000 claims description 8
• 229910052731 fluorine Inorganic materials 0.000 claims description 8
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
• 208000011580 syndromic disease Diseases 0.000 claims description 8
• 208000005189 Embolism Diseases 0.000 claims description 7
• 206010061218 Inflammation Diseases 0.000 claims description 7
• 239000003795 chemical substances by application Substances 0.000 claims description 7
• 230000004054 inflammatory process Effects 0.000 claims description 7
• 230000003959 neuroinflammation Effects 0.000 claims description 7
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 7
• JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 6
• 201000001320 Atherosclerosis Diseases 0.000 claims description 6
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 6
• 206010040047 Sepsis Diseases 0.000 claims description 6
• 201000005008 bacterial sepsis Diseases 0.000 claims description 6
• 210000003709 heart valve Anatomy 0.000 claims description 6
• 238000004519 manufacturing process Methods 0.000 claims description 6
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 6
• 230000004770 neurodegeneration Effects 0.000 claims description 6
• 208000032382 Ischaemic stroke Diseases 0.000 claims description 5
• 208000019695 Migraine disease Diseases 0.000 claims description 5
• 206010028980 Neoplasm Diseases 0.000 claims description 5
• 201000010183 Papilledema Diseases 0.000 claims description 5
• 206010038886 Retinal oedema Diseases 0.000 claims description 5
• 208000001435 Thromboembolism Diseases 0.000 claims description 5
• 238000011882 arthroplasty Methods 0.000 claims description 5
• 201000011510 cancer Diseases 0.000 claims description 5
• 238000000502 dialysis Methods 0.000 claims description 5
• 206010015037 epilepsy Diseases 0.000 claims description 5
• 238000002618 extracorporeal membrane oxygenation Methods 0.000 claims description 5
• 230000002008 hemorrhagic effect Effects 0.000 claims description 5
• 206010027599 migraine Diseases 0.000 claims description 5
• 201000011195 retinal edema Diseases 0.000 claims description 5
• 208000007056 sickle cell anemia Diseases 0.000 claims description 5
• 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 4
• 208000024827 Alzheimer disease Diseases 0.000 claims description 4
• 229910052794 bromium Inorganic materials 0.000 claims description 4
• 125000001153 fluoro group Chemical group F* 0.000 claims description 4
• 229910052740 iodine Inorganic materials 0.000 claims description 4
• 230000002314 neuroinflammatory effect Effects 0.000 claims description 4
• 230000002265 prevention Effects 0.000 claims description 3
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
• 206010050216 Paget-Schroetter syndrome Diseases 0.000 claims description 2
• 208000004519 Upper Extremity Deep Vein Thrombosis Diseases 0.000 claims description 2
• 229910052805 deuterium Inorganic materials 0.000 claims description 2
• 230000000155 isotopic effect Effects 0.000 claims description 2
• 210000001957 retinal vein Anatomy 0.000 claims description 2
• RXXCIBALSKQCAE-UHFFFAOYSA-N 3-methylbutoxymethylbenzene Chemical compound CC(C)CCOCC1=CC=CC=C1 RXXCIBALSKQCAE-UHFFFAOYSA-N 0.000 claims 1
• 230000006698 induction Effects 0.000 claims 1
• 230000001568 sexual effect Effects 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 abstract description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 76
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 68
• 238000005481 NMR spectroscopy Methods 0.000 description 43
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 39
• 238000007429 general method Methods 0.000 description 36
• 239000007787 solid Substances 0.000 description 35
• 239000003112 inhibitor Substances 0.000 description 34
• 238000006243 chemical reaction Methods 0.000 description 31
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 29
• 150000001412 amines Chemical class 0.000 description 29
• 239000000243 solution Substances 0.000 description 22
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
• 108090000113 Plasma Kallikrein Proteins 0.000 description 18
• 102000003827 Plasma Kallikrein Human genes 0.000 description 17
• 108010080865 Factor XII Proteins 0.000 description 15
• 102000000429 Factor XII Human genes 0.000 description 15
• 239000002253 acid Substances 0.000 description 15
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
• 125000004433 nitrogen atom Chemical group N* 0.000 description 14
• LWDVTRXNUGVQES-UHFFFAOYSA-N 6-(aminomethyl)isoquinolin-1-amine Chemical compound NC1=NC=CC2=CC(CN)=CC=C21 LWDVTRXNUGVQES-UHFFFAOYSA-N 0.000 description 13
• 206010012688 Diabetic retinal oedema Diseases 0.000 description 13
• 238000009472 formulation Methods 0.000 description 13
• 230000035772 mutation Effects 0.000 description 13
• 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 13
• 230000004913 activation Effects 0.000 description 12
• 201000011190 diabetic macular edema Diseases 0.000 description 12
• 230000008569 process Effects 0.000 description 12
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
• 238000010168 coupling process Methods 0.000 description 11
• 239000002904 solvent Substances 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• 108050007539 Plasma protease C1 inhibitor Proteins 0.000 description 10
• 102100027637 Plasma protease C1 inhibitor Human genes 0.000 description 10
• 230000008878 coupling Effects 0.000 description 10
• 238000005859 coupling reaction Methods 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
• 229940009550 c1 esterase inhibitor Drugs 0.000 description 9
• 230000005764 inhibitory process Effects 0.000 description 9
• 239000000543 intermediate Substances 0.000 description 9
• 238000012799 strong cation exchange Methods 0.000 description 9
• BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 8
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
• 238000003818 flash chromatography Methods 0.000 description 8
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 7
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
• 206010030113 Oedema Diseases 0.000 description 7
• 239000007864 aqueous solution Substances 0.000 description 7
• 125000003118 aryl group Chemical group 0.000 description 7
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
• 239000003921 oil Substances 0.000 description 7
• 235000019198 oils Nutrition 0.000 description 7
• 125000006239 protecting group Chemical group 0.000 description 7
• 239000011541 reaction mixture Substances 0.000 description 7
• 239000003643 water by type Substances 0.000 description 7
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 108700040183 Complement C1 Inhibitor Proteins 0.000 description 6
• 102000055157 Complement C1 Inhibitor Human genes 0.000 description 6
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 230000002401 inhibitory effect Effects 0.000 description 6
• MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 5
• IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 5
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
• 230000005856 abnormality Effects 0.000 description 5
• 206010064930 age-related macular degeneration Diseases 0.000 description 5
• 230000029936 alkylation Effects 0.000 description 5
• 238000005804 alkylation reaction Methods 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 238000002648 combination therapy Methods 0.000 description 5
• 239000012043 crude product Substances 0.000 description 5
• 230000007547 defect Effects 0.000 description 5
• 230000007812 deficiency Effects 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 208000002780 macular degeneration Diseases 0.000 description 5
• 230000037361 pathway Effects 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
• KJZLJGZZDNGGCA-UHFFFAOYSA-N (1-methylpiperidin-4-yl)methanol Chemical compound CN1CCC(CO)CC1 KJZLJGZZDNGGCA-UHFFFAOYSA-N 0.000 description 4
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
• KVCOOWROABTXDJ-UHFFFAOYSA-N 6-chloropyridin-3-ol Chemical compound OC1=CC=C(Cl)N=C1 KVCOOWROABTXDJ-UHFFFAOYSA-N 0.000 description 4
• 108010074864 Factor XI Proteins 0.000 description 4
• BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
• IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• 230000002378 acidificating effect Effects 0.000 description 4
• 208000026935 allergic disease Diseases 0.000 description 4
• 230000007815 allergy Effects 0.000 description 4
• 150000001408 amides Chemical class 0.000 description 4
• 239000003146 anticoagulant agent Substances 0.000 description 4
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
• 239000003054 catalyst Substances 0.000 description 4
• 239000012230 colorless oil Substances 0.000 description 4
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 230000004064 dysfunction Effects 0.000 description 4
• 235000019439 ethyl acetate Nutrition 0.000 description 4
• 239000005556 hormone Substances 0.000 description 4
• 229940088597 hormone Drugs 0.000 description 4
• 229910052739 hydrogen Inorganic materials 0.000 description 4
• 239000001257 hydrogen Substances 0.000 description 4
• 239000003960 organic solvent Substances 0.000 description 4
• 229910000027 potassium carbonate Inorganic materials 0.000 description 4
• 239000000651 prodrug Substances 0.000 description 4
• 229940002612 prodrug Drugs 0.000 description 4
• 210000001525 retina Anatomy 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 229910000104 sodium hydride Inorganic materials 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
• OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 208000023275 Autoimmune disease Diseases 0.000 description 3
• 239000012388 BrettPhos 3rd generation precatalyst Substances 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
• 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• 239000007821 HATU Substances 0.000 description 3
• 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 3
• 101710151321 Melanostatin Proteins 0.000 description 3
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
• 102400000064 Neuropeptide Y Human genes 0.000 description 3
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
• 102000013566 Plasminogen Human genes 0.000 description 3
• 108010051456 Plasminogen Proteins 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 102000002020 Protease-activated receptors Human genes 0.000 description 3
• 108050009310 Protease-activated receptors Proteins 0.000 description 3
• 206010038908 Retinal vein thrombosis Diseases 0.000 description 3
• 102000012479 Serine Proteases Human genes 0.000 description 3
• 108010022999 Serine Proteases Proteins 0.000 description 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 239000003638 chemical reducing agent Substances 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 230000004154 complement system Effects 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 238000005984 hydrogenation reaction Methods 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
• 239000002955 immunomodulating agent Substances 0.000 description 3
• 229940121354 immunomodulator Drugs 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 3
• 239000007937 lozenge Substances 0.000 description 3
• 150000007530 organic bases Chemical class 0.000 description 3
• 239000012044 organic layer Substances 0.000 description 3
• 229910052763 palladium Inorganic materials 0.000 description 3
• 230000035699 permeability Effects 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 3
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 208000004644 retinal vein occlusion Diseases 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 3
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 230000002792 vascular Effects 0.000 description 3
• GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
• 125000005940 1,4-dioxanyl group Chemical group 0.000 description 2
• VBEHFOMFHUQAOW-UHFFFAOYSA-N 2-chloro-1h-pyridin-4-one Chemical compound OC1=CC=NC(Cl)=C1 VBEHFOMFHUQAOW-UHFFFAOYSA-N 0.000 description 2
• XYSORHCTKOJKOD-UHFFFAOYSA-N 2-chloro-4-(1-methylpiperidin-4-yl)oxypyridine Chemical compound C1CN(C)CCC1OC1=CC=NC(Cl)=C1 XYSORHCTKOJKOD-UHFFFAOYSA-N 0.000 description 2
• AEAZWGYXRRGTDI-UHFFFAOYSA-N 2-chloro-5-(piperidin-4-ylmethoxy)pyridine Chemical compound C1=NC(Cl)=CC=C1OCC1CCNCC1 AEAZWGYXRRGTDI-UHFFFAOYSA-N 0.000 description 2
• MBSDSHYGSGQSEI-UHFFFAOYSA-N 4-(4-bromophenoxy)-1-methylpiperidine Chemical compound C1CN(C)CCC1OC1=CC=C(Br)C=C1 MBSDSHYGSGQSEI-UHFFFAOYSA-N 0.000 description 2
• LAXWAYHNIVBBPC-UHFFFAOYSA-N 6-(aminomethyl)isoquinolin-1-amine;dihydrochloride Chemical compound Cl.Cl.NC1=NC=CC2=CC(CN)=CC=C21 LAXWAYHNIVBBPC-UHFFFAOYSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• JWEOHKKTKDSLEY-UHFFFAOYSA-N BrC=1C=CC(=C(C=1)CO)OCC1CCN(CC1)C Chemical compound BrC=1C=CC(=C(C=1)CO)OCC1CCN(CC1)C JWEOHKKTKDSLEY-UHFFFAOYSA-N 0.000 description 2
• NJEARGVYUGROKH-UHFFFAOYSA-N CN1CCC(CC1)COC=1C=CC(=NC=1)NCC=1C=C2C=CN=C(C2=CC=1)N Chemical compound CN1CCC(CC1)COC=1C=CC(=NC=1)NCC=1C=C2C=CN=C(C2=CC=1)N NJEARGVYUGROKH-UHFFFAOYSA-N 0.000 description 2
• WPEZVMZSAYHNNY-UHFFFAOYSA-N CN1CCC(COC(C=C2)=C(CO)C=C2NCC(C=C2C=CC3)=CC=C2N3N)CC1 Chemical compound CN1CCC(COC(C=C2)=C(CO)C=C2NCC(C=C2C=CC3)=CC=C2N3N)CC1 WPEZVMZSAYHNNY-UHFFFAOYSA-N 0.000 description 2
• MTQLUYFANRADID-UHFFFAOYSA-N ClC1=NC=C(C=C1)OCC1CCN(CC1)C Chemical compound ClC1=NC=C(C=C1)OCC1CCN(CC1)C MTQLUYFANRADID-UHFFFAOYSA-N 0.000 description 2
• 102000016918 Complement C3 Human genes 0.000 description 2
• 108010028780 Complement C3 Proteins 0.000 description 2
• RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• 101150072419 F12 gene Proteins 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• 101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 description 2
• 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 description 2
• 101000713170 Homo sapiens Solute carrier family 52, riboflavin transporter, member 1 Proteins 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• YSMULXMSVAGWOW-UHFFFAOYSA-N N1CCC(CC1)OC1=CC(=NC=C1)NCC=1C=C2C=CN=C(C2=CC=1)N Chemical compound N1CCC(CC1)OC1=CC(=NC=C1)NCC=1C=C2C=CN=C(C2=CC=1)N YSMULXMSVAGWOW-UHFFFAOYSA-N 0.000 description 2
• FAFDIGWRERLYGH-UHFFFAOYSA-N NC1=NC=CC2=CC(=CC=C12)CNC1=CC=C(C=N1)COC1CCN(CC1)C(=O)OC(C)(C)C Chemical compound NC1=NC=CC2=CC(=CC=C12)CNC1=CC=C(C=N1)COC1CCN(CC1)C(=O)OC(C)(C)C FAFDIGWRERLYGH-UHFFFAOYSA-N 0.000 description 2
• OAFHTFIFDAHTGF-UHFFFAOYSA-N NC1=NC=CC2=CC(=CC=C12)CNC1=CC=CC(=N1)C(=O)O Chemical compound NC1=NC=CC2=CC(=CC=C12)CNC1=CC=CC(=N1)C(=O)O OAFHTFIFDAHTGF-UHFFFAOYSA-N 0.000 description 2
• ARKWRYOZEUWXGU-UHFFFAOYSA-N NC1=NC=CC2=CC(=CC=C12)CNC1=NC=C(C(=O)OC)C=C1 Chemical compound NC1=NC=CC2=CC(=CC=C12)CNC1=NC=C(C(=O)OC)C=C1 ARKWRYOZEUWXGU-UHFFFAOYSA-N 0.000 description 2
• 235000019502 Orange oil Nutrition 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 229930040373 Paraformaldehyde Natural products 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 2
• 101150097162 SERPING1 gene Proteins 0.000 description 2
• FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 208000005707 acquired angioedema Diseases 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 150000001347 alkyl bromides Chemical class 0.000 description 2
• 150000001350 alkyl halides Chemical class 0.000 description 2
• 125000006242 amine protecting group Chemical group 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
• RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 229940127218 antiplatelet drug Drugs 0.000 description 2
• 125000002393 azetidinyl group Chemical group 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
• 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 150000001805 chlorine compounds Chemical class 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 229940125758 compound 15 Drugs 0.000 description 2
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 230000006806 disease prevention Effects 0.000 description 2
• 108010011867 ecallantide Proteins 0.000 description 2
• 238000000132 electrospray ionisation Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 229940011871 estrogen Drugs 0.000 description 2
• 239000000262 estrogen Substances 0.000 description 2
• 235000019253 formic acid Nutrition 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 210000004392 genitalia Anatomy 0.000 description 2
• 239000007902 hard capsule Substances 0.000 description 2
• 230000023597 hemostasis Effects 0.000 description 2
• QURWXBZNHXJZBE-SKXRKSCCSA-N icatibant Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 QURWXBZNHXJZBE-SKXRKSCCSA-N 0.000 description 2
• 125000002632 imidazolidinyl group Chemical group 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• VBGWSQKGUZHFPS-VGMMZINCSA-N kalbitor Chemical compound C([C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)NCC(=O)NCC(=O)N[C@H]3CSSC[C@H](NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CO)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)CSSC[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC3=O)CSSC2)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)[C@@H](C)CC)[C@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 VBGWSQKGUZHFPS-VGMMZINCSA-N 0.000 description 2
• 229950005287 lanadelumab Drugs 0.000 description 2
• 238000002647 laser therapy Methods 0.000 description 2
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 150000002825 nitriles Chemical class 0.000 description 2
• URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 239000010502 orange oil Substances 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 230000000399 orthopedic effect Effects 0.000 description 2
• 125000003566 oxetanyl group Chemical group 0.000 description 2
• 206010033675 panniculitis Diseases 0.000 description 2
• 229920002866 paraformaldehyde Polymers 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000009038 pharmacological inhibition Effects 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 125000004193 piperazinyl group Chemical group 0.000 description 2
• 229940012957 plasmin Drugs 0.000 description 2
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
• 229920000747 poly(lactic acid) Polymers 0.000 description 2
• IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 108090000623 proteins and genes Proteins 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000007901 soft capsule Substances 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 210000004304 subcutaneous tissue Anatomy 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 2
• RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 2
• 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
• 230000002537 thrombolytic effect Effects 0.000 description 2
• 229960000187 tissue plasminogen activator Drugs 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
• 210000004127 vitreous body Anatomy 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• AGTPSAZJSOQXHJ-UHFFFAOYSA-N (1-methylpiperidin-4-yl)methanamine Chemical compound CN1CCC(CN)CC1 AGTPSAZJSOQXHJ-UHFFFAOYSA-N 0.000 description 1
• UDDVPFLXGOBESH-UHFFFAOYSA-N (2-chloropyridin-4-yl)methanol Chemical compound OCC1=CC=NC(Cl)=C1 UDDVPFLXGOBESH-UHFFFAOYSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• GOXYBEXWMJZLJB-UHFFFAOYSA-N (6-chloropyridin-3-yl)methanol Chemical compound OCC1=CC=C(Cl)N=C1 GOXYBEXWMJZLJB-UHFFFAOYSA-N 0.000 description 1
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• AITNMTXHTIIIBB-UHFFFAOYSA-N 1-bromo-4-fluorobenzene Chemical compound FC1=CC=C(Br)C=C1 AITNMTXHTIIIBB-UHFFFAOYSA-N 0.000 description 1
• ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 1
• ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
• ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
• JVSDZAGCHKCSGR-UHFFFAOYSA-N 2,5-dichloropyrazine Chemical compound ClC1=CN=C(Cl)C=N1 JVSDZAGCHKCSGR-UHFFFAOYSA-N 0.000 description 1
• LSEAAPGIZCDEEH-UHFFFAOYSA-N 2,6-dichloropyrazine Chemical compound ClC1=CN=CC(Cl)=N1 LSEAAPGIZCDEEH-UHFFFAOYSA-N 0.000 description 1
• FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 1
• LIEPVGBDUYKPLC-UHFFFAOYSA-N 2-chloro-4-nitropyridine Chemical compound [O-][N+](=O)C1=CC=NC(Cl)=C1 LIEPVGBDUYKPLC-UHFFFAOYSA-N 0.000 description 1
• HYDJZXSAHZSTKF-UHFFFAOYSA-N 2-chloro-5-(1-methylpiperidin-4-yl)oxypyridine Chemical compound C1CN(C)CCC1OC1=CC=C(Cl)N=C1 HYDJZXSAHZSTKF-UHFFFAOYSA-N 0.000 description 1
• BVZBDAUMHWIPCS-UHFFFAOYSA-N 2-chloro-5-(1-methylpiperidin-4-yl)oxypyrimidine Chemical compound C1CN(C)CCC1OC1=CN=C(Cl)N=C1 BVZBDAUMHWIPCS-UHFFFAOYSA-N 0.000 description 1
• SKCNYHLTRZIINA-UHFFFAOYSA-N 2-chloro-5-(chloromethyl)pyridine Chemical compound ClCC1=CC=C(Cl)N=C1 SKCNYHLTRZIINA-UHFFFAOYSA-N 0.000 description 1
• BZZFXYANCDSDDL-UHFFFAOYSA-N 2-chloro-6-(1-methylpiperidin-4-yl)oxypyrazine Chemical compound C1CN(C)CCC1OC1=CN=CC(Cl)=N1 BZZFXYANCDSDDL-UHFFFAOYSA-N 0.000 description 1
• KTVWKYXYLAPUJW-UHFFFAOYSA-N 2-chloro-n-(1-methylpiperidin-4-yl)pyridine-4-carboxamide Chemical compound C1CN(C)CCC1NC(=O)C1=CC=NC(Cl)=C1 KTVWKYXYLAPUJW-UHFFFAOYSA-N 0.000 description 1
• QXCOHSRHFCHCHN-UHFFFAOYSA-N 2-chloropyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(Cl)=C1 QXCOHSRHFCHCHN-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
• LGCYVLDNGBSOOW-UHFFFAOYSA-N 2H-benzotriazol-4-ol 1-hydroxybenzotriazole Chemical compound OC1=CC=CC2=C1N=NN2.C1=CC=C2N(O)N=NC2=C1 LGCYVLDNGBSOOW-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
• XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical group C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
• ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
• KELAIWLMVFYRJD-UHFFFAOYSA-N 4-(4-bromophenoxy)piperidine Chemical compound C1=CC(Br)=CC=C1OC1CCNCC1 KELAIWLMVFYRJD-UHFFFAOYSA-N 0.000 description 1
• LIBKIDPJYQPTJW-UHFFFAOYSA-N 4-[2-(6-chloropyridin-3-yl)oxyethyl]morpholine Chemical compound C1=NC(Cl)=CC=C1OCCN1CCOCC1 LIBKIDPJYQPTJW-UHFFFAOYSA-N 0.000 description 1
• XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
• QGFYFOHMBDMGBZ-UHFFFAOYSA-N 5-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)phenol Chemical compound C1=C(O)C(CN(CC)CC)=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 QGFYFOHMBDMGBZ-UHFFFAOYSA-N 0.000 description 1
• MYUQKYGWKHTRPG-UHFFFAOYSA-N 5-bromo-2-fluoropyridine Chemical compound FC1=CC=C(Br)C=N1 MYUQKYGWKHTRPG-UHFFFAOYSA-N 0.000 description 1
• AULWPXHFRBLPAE-UHFFFAOYSA-N 6-chloropyridine Chemical compound ClC1=C=CC=C[N]1 AULWPXHFRBLPAE-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
• 101150037123 APOE gene Proteins 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
• KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 102000008873 Angiotensin II receptor Human genes 0.000 description 1
• 108050000824 Angiotensin II receptor Proteins 0.000 description 1
• 108010064733 Angiotensins Proteins 0.000 description 1
• 102000015427 Angiotensins Human genes 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• CQGKCZRQTNTXCS-UHFFFAOYSA-N BrC1=CC=C(OCC2CCN(CC2)C)C=C1 Chemical compound BrC1=CC=C(OCC2CCN(CC2)C)C=C1 CQGKCZRQTNTXCS-UHFFFAOYSA-N 0.000 description 1
• ZJGFDXMEEQSHTE-UHFFFAOYSA-N BrC=1C=CC(=NC=1)OCC1CCN(CC1)C Chemical compound BrC=1C=CC(=NC=1)OCC1CCN(CC1)C ZJGFDXMEEQSHTE-UHFFFAOYSA-N 0.000 description 1
• 201000007120 C1 inhibitor deficiency Diseases 0.000 description 1
• QPDKWDUILFQIRW-UHFFFAOYSA-N CN1C=CC(OCC(C=C2)=CN=C2Cl)=CC1 Chemical compound CN1C=CC(OCC(C=C2)=CN=C2Cl)=CC1 QPDKWDUILFQIRW-UHFFFAOYSA-N 0.000 description 1
• YJSLJIJRTZBVRZ-UHFFFAOYSA-N CN1CCC(CC1)COC1=CC=C(C=C1)NCC=1C=C2C=CN=C(C2=CC=1)N Chemical compound CN1CCC(CC1)COC1=CC=C(C=C1)NCC=1C=C2C=CN=C(C2=CC=1)N YJSLJIJRTZBVRZ-UHFFFAOYSA-N 0.000 description 1
• SANORLLDWLOWDL-UHFFFAOYSA-N CN1CCC(CC1)COC1=CC=C(C=N1)NCC=1C=C2C=CN=C(C2=CC=1)N Chemical compound CN1CCC(CC1)COC1=CC=C(C=N1)NCC=1C=C2C=CN=C(C2=CC=1)N SANORLLDWLOWDL-UHFFFAOYSA-N 0.000 description 1
• FWYZNELLSVCDCD-UHFFFAOYSA-N CN1CCC(CC1)COC=1N=CC(=NC=1)NCC=1C=C2C=CN=C(C2=CC=1)N Chemical compound CN1CCC(CC1)COC=1N=CC(=NC=1)NCC=1C=C2C=CN=C(C2=CC=1)N FWYZNELLSVCDCD-UHFFFAOYSA-N 0.000 description 1
• MIAMFHQLFSTCTM-UHFFFAOYSA-N CN1CCC(CC1)OC1=CC(=NC=C1)NCC=1C=C2C=CN=C(C2=CC=1)N Chemical compound CN1CCC(CC1)OC1=CC(=NC=C1)NCC=1C=C2C=CN=C(C2=CC=1)N MIAMFHQLFSTCTM-UHFFFAOYSA-N 0.000 description 1
• GNJQMNZBERORSH-UHFFFAOYSA-N CN1CCC(CC1)OC1=CC=C(C=C1)NCC=1C=C2C=CN=C(C2=CC=1)N Chemical compound CN1CCC(CC1)OC1=CC=C(C=C1)NCC=1C=C2C=CN=C(C2=CC=1)N GNJQMNZBERORSH-UHFFFAOYSA-N 0.000 description 1
• LPTPUXIDRJVDER-UHFFFAOYSA-N CN1CCC(CC1)OC1=CN=CC(=N1)NCC=1C=C2C=CN=C(C2=CC=1)N Chemical compound CN1CCC(CC1)OC1=CN=CC(=N1)NCC=1C=C2C=CN=C(C2=CC=1)N LPTPUXIDRJVDER-UHFFFAOYSA-N 0.000 description 1
• KXBHNVTUYBOYMS-UHFFFAOYSA-N CN1CCC(CC1)OC=1C=CC(=NC=1)NCC=1C=C2C=CN=C(C2=CC=1)N Chemical compound CN1CCC(CC1)OC=1C=CC(=NC=1)NCC=1C=C2C=CN=C(C2=CC=1)N KXBHNVTUYBOYMS-UHFFFAOYSA-N 0.000 description 1
• RADBOWDLSSJNSE-UHFFFAOYSA-N CN1CCC(CC1)OC=1C=NC(=NC=1)NCC=1C=C2C=CN=C(C2=CC=1)N Chemical compound CN1CCC(CC1)OC=1C=NC(=NC=1)NCC=1C=C2C=CN=C(C2=CC=1)N RADBOWDLSSJNSE-UHFFFAOYSA-N 0.000 description 1
• NHQSFJNYYRPKDO-UHFFFAOYSA-N CN1CCC(CC1)OCC1=CC(=NC=C1)NCC=1C=C2C=CN=C(C2=CC=1)N Chemical compound CN1CCC(CC1)OCC1=CC(=NC=C1)NCC=1C=C2C=CN=C(C2=CC=1)N NHQSFJNYYRPKDO-UHFFFAOYSA-N 0.000 description 1
• RVIDVWYPEHLACS-UHFFFAOYSA-N CN1CCC(CC1)OCC=1C=CC(=NC=1)NCC=1C=C2C=CN=C(C2=CC=1)N Chemical compound CN1CCC(CC1)OCC=1C=CC(=NC=1)NCC=1C=C2C=CN=C(C2=CC=1)N RVIDVWYPEHLACS-UHFFFAOYSA-N 0.000 description 1
• 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• MPONAPFARZGDTH-UHFFFAOYSA-N Cl.OS(O)=O Chemical compound Cl.OS(O)=O MPONAPFARZGDTH-UHFFFAOYSA-N 0.000 description 1
• SKJVQCWVFFZPKU-UHFFFAOYSA-N ClC1=NC=C(N=C1)OCC1CCN(CC1)C Chemical compound ClC1=NC=C(N=C1)OCC1CCN(CC1)C SKJVQCWVFFZPKU-UHFFFAOYSA-N 0.000 description 1
• UKYFKQFDUUNMOP-UHFFFAOYSA-N ClC1=NC=CC(=C1)COC1CCN(CC1)C Chemical compound ClC1=NC=CC(=C1)COC1CCN(CC1)C UKYFKQFDUUNMOP-UHFFFAOYSA-N 0.000 description 1
• 102100030556 Coagulation factor XII Human genes 0.000 description 1
• 108010028774 Complement C1 Proteins 0.000 description 1
• 102100025406 Complement C1s subcomponent Human genes 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
• 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
• 108700036031 EC 3.4.21.38 Proteins 0.000 description 1
• 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
• 102000010911 Enzyme Precursors Human genes 0.000 description 1
• 108010062466 Enzyme Precursors Proteins 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 229940123849 Factor IXa inhibitor Drugs 0.000 description 1
• 229940082863 Factor VIIa inhibitor Drugs 0.000 description 1
• 108010080805 Factor XIa Proteins 0.000 description 1
• 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 1
• 101001098529 Homo sapiens Proteinase-activated receptor 1 Proteins 0.000 description 1
• 101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
• 241000764238 Isis Species 0.000 description 1
• 102000001399 Kallikrein Human genes 0.000 description 1
• 108060005987 Kallikrein Proteins 0.000 description 1
• 229940127379 Kallikrein Inhibitors Drugs 0.000 description 1
• 229930194542 Keto Natural products 0.000 description 1
• 108010093008 Kinins Proteins 0.000 description 1
• 102000002397 Kinins Human genes 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
• QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• YEQUSASGCNDCGR-UHFFFAOYSA-N N1CCC(CC1)OCC=1C=CC(=NC=1)NCC=1C=C2C=CN=C(C2=CC=1)N Chemical compound N1CCC(CC1)OCC=1C=CC(=NC=1)NCC=1C=C2C=CN=C(C2=CC=1)N YEQUSASGCNDCGR-UHFFFAOYSA-N 0.000 description 1
• YTDFAYQNNVMUDL-UHFFFAOYSA-N NC1=NC=CC2=CC(=CC=C12)CNC1=CC=CC(=N1)C#N Chemical compound NC1=NC=CC2=CC(=CC=C12)CNC1=CC=CC(=N1)C#N YTDFAYQNNVMUDL-UHFFFAOYSA-N 0.000 description 1
• QKSISCPOVVBTSY-UHFFFAOYSA-M NC1=NC=CC2=CC(=CC=C12)CNC1=NC=C(C(=O)[O-])C=C1.[Li+] Chemical compound NC1=NC=CC2=CC(=CC=C12)CNC1=NC=C(C(=O)[O-])C=C1.[Li+] QKSISCPOVVBTSY-UHFFFAOYSA-M 0.000 description 1
• NIJYPZVEGPDASP-UHFFFAOYSA-N NC1=NC=CC2=CC(=CC=C12)CNC1=NC=CC(=C1)OC1CCN(CC1)C(=O)OC(C)(C)C Chemical compound NC1=NC=CC2=CC(=CC=C12)CNC1=NC=CC(=C1)OC1CCN(CC1)C(=O)OC(C)(C)C NIJYPZVEGPDASP-UHFFFAOYSA-N 0.000 description 1
• 239000006057 Non-nutritive feed additive Substances 0.000 description 1
• IQJXMBWGNVEJGD-UHFFFAOYSA-N O1CCN(CC1)CCOC=1C=CC(=NC=1)NCC=1C=C2C=CN=C(C2=CC=1)N Chemical compound O1CCN(CC1)CCOC=1C=CC(=NC=1)NCC=1C=C2C=CN=C(C2=CC=1)N IQJXMBWGNVEJGD-UHFFFAOYSA-N 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 102100034869 Plasma kallikrein Human genes 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• HMNSRTLZAJHSIK-YUMQZZPRSA-N Pro-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 HMNSRTLZAJHSIK-YUMQZZPRSA-N 0.000 description 1
• 102100037136 Proteinase-activated receptor 1 Human genes 0.000 description 1
• 108010026552 Proteome Proteins 0.000 description 1
• 108010094028 Prothrombin Proteins 0.000 description 1
• 102100027378 Prothrombin Human genes 0.000 description 1
• 206010038563 Reocclusion Diseases 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 208000002847 Surgical Wound Diseases 0.000 description 1
• HYLXOQURIOCKIH-VQVTYTSYSA-N Thr-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N HYLXOQURIOCKIH-VQVTYTSYSA-N 0.000 description 1
• 229940122388 Thrombin inhibitor Drugs 0.000 description 1
• 241000009298 Trigla lyra Species 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 208000007814 Unstable Angina Diseases 0.000 description 1
• 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
• 108010059382 Zea mays trypsin inhibitor Proteins 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 230000007488 abnormal function Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 238000005903 acid hydrolysis reaction Methods 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000003915 air pollution Methods 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001335 aliphatic alkanes Chemical class 0.000 description 1
• 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 238000010640 amide synthesis reaction Methods 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 229960004676 antithrombotic agent Drugs 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 239000012300 argon atmosphere Substances 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 238000011914 asymmetric synthesis Methods 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
• KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• 229940075791 berinert Drugs 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
• 230000027455 binding Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 238000010170 biological method Methods 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 229910000085 borane Inorganic materials 0.000 description 1
• 239000012267 brine Substances 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
• 229910000024 caesium carbonate Inorganic materials 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 230000002612 cardiopulmonary effect Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 210000004027 cell Anatomy 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 150000001793 charged compounds Chemical class 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000007910 chewable tablet Substances 0.000 description 1
• 229940088949 cinryze Drugs 0.000 description 1
• 229940125833 compound 23 Drugs 0.000 description 1
• 108700005721 conestat alfa Proteins 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 229920006237 degradable polymer Polymers 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 230000005595 deprotonation Effects 0.000 description 1
• 238000010537 deprotonation reaction Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
• 229940071221 dihydroxybenzoate Drugs 0.000 description 1
• UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 229960001174 ecallantide Drugs 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 150000002085 enols Chemical class 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000010931 ester hydrolysis Methods 0.000 description 1
• 239000002329 esterase inhibitor Substances 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
• OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 239000002319 fibrinogen receptor antagonist Substances 0.000 description 1
• 230000020764 fibrinolysis Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 229940050762 firazyr Drugs 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 210000004247 hand Anatomy 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
• 208000030407 hereditary angioedema with normal C1Inh Diseases 0.000 description 1
• 125000001072 heteroaryl group Chemical group 0.000 description 1
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
• 102000044507 human SERPING1 Human genes 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 108700023918 icatibant Proteins 0.000 description 1
• 229960001062 icatibant Drugs 0.000 description 1
• 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 238000012739 integrated shape imaging system Methods 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007919 intrasynovial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000007915 intraurethral administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 239000001573 invertase Substances 0.000 description 1
• 235000011073 invertase Nutrition 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• OSILBMSORKFRTB-UHFFFAOYSA-N isoquinolin-1-amine Chemical compound C1=CC=C2C(N)=NC=CC2=C1 OSILBMSORKFRTB-UHFFFAOYSA-N 0.000 description 1
• 229940018902 kalbitor Drugs 0.000 description 1
• 125000000468 ketone group Chemical group 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
• UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
• FJYDBKPPGRZSOZ-UHFFFAOYSA-N methyl 5-bromo-2-hydroxybenzoate Chemical compound COC(=O)C1=CC(Br)=CC=C1O FJYDBKPPGRZSOZ-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 238000003032 molecular docking Methods 0.000 description 1
• WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 231100000623 nanotoxicology Toxicity 0.000 description 1
• YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical class C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
• 238000010641 nitrile hydrolysis reaction Methods 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
• 239000003182 parenteral nutrition solution Substances 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 1
• 230000033885 plasminogen activation Effects 0.000 description 1
• 229920001610 polycaprolactone Polymers 0.000 description 1
• 239000004632 polycaprolactone Substances 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• LBKJNHPKYFYCLL-UHFFFAOYSA-N potassium;trimethyl(oxido)silane Chemical compound [K+].C[Si](C)(C)[O-] LBKJNHPKYFYCLL-UHFFFAOYSA-N 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 239000003805 procoagulant Substances 0.000 description 1
• 108010004914 prolylarginine Proteins 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 230000006916 protein interaction Effects 0.000 description 1
• 229940039716 prothrombin Drugs 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• 238000005086 pumping Methods 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 229960003876 ranibizumab Drugs 0.000 description 1
• 239000003087 receptor blocking agent Substances 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 238000006268 reductive amination reaction Methods 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 210000001210 retinal vessel Anatomy 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 229940009560 ruconest Drugs 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 208000015891 sexual disease Diseases 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
• 239000008137 solubility enhancer Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000008227 sterile water for injection Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 229940086735 succinate Drugs 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• XTDXZSGSIMLARD-UHFFFAOYSA-N tert-butyl 2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC=CC=C1 XTDXZSGSIMLARD-UHFFFAOYSA-N 0.000 description 1
• QJGJETWHNOHKQR-UHFFFAOYSA-N tert-butyl 4-(2-chloropyridin-4-yl)oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC=NC(Cl)=C1 QJGJETWHNOHKQR-UHFFFAOYSA-N 0.000 description 1
• COZKMQIFQZKKBR-UHFFFAOYSA-N tert-butyl 4-(4-bromophenoxy)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC=C(Br)C=C1 COZKMQIFQZKKBR-UHFFFAOYSA-N 0.000 description 1
• YGJXBTRLYHCWGD-UHFFFAOYSA-N tert-butyl 4-(bromomethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CBr)CC1 YGJXBTRLYHCWGD-UHFFFAOYSA-N 0.000 description 1
• LPRZYIIKRRRFCV-UHFFFAOYSA-N tert-butyl 4-[(6-chloropyridin-3-yl)methoxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OCC1=CC=C(Cl)N=C1 LPRZYIIKRRRFCV-UHFFFAOYSA-N 0.000 description 1
• MJBBXJHZJGYKND-UHFFFAOYSA-N tert-butyl 4-[(6-chloropyridin-3-yl)oxymethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1COC1=CC=C(Cl)N=C1 MJBBXJHZJGYKND-UHFFFAOYSA-N 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• 239000003868 thrombin inhibitor Substances 0.000 description 1
• 239000003856 thrombin receptor antagonist Substances 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
• 229960005294 triamcinolone Drugs 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 108010036927 trypsin-like serine protease Proteins 0.000 description 1
• 108020005087 unfolded proteins Proteins 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 230000008728 vascular permeability Effects 0.000 description 1
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
• 239000002525 vasculotropin inhibitor Substances 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 229950000339 xinafoate Drugs 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1